Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

To B-(RAF) or not to be.

Dummer R, Goldinger SM, Widmer D, Dreier J, Levesque MP.

J Invest Dermatol. 2014 May;134(5):1200-1. doi: 10.1038/jid.2014.62.

2.

[Treatment of metastatic melanoma with BRAF inhibitors].

Hafner C.

Hautarzt. 2011 Sep;62(9):696-8. doi: 10.1007/s00105-011-2232-8. German. No abstract available.

PMID:
21863388
3.

Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?

Saint-Jean M, Quéreux G, Nguyen JM, Peuvrel L, Brocard A, Vallée A, Knol AC, Khammari A, Denis MG, Dréno B.

J Invest Dermatol. 2014 May;134(5):1468-70. doi: 10.1038/jid.2013.378. Epub 2013 Sep 11. No abstract available.

4.

BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.

Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, Mourah S.

Melanoma Res. 2014 Aug;24(4):415-8. doi: 10.1097/CMR.0000000000000088. No abstract available.

PMID:
24933605
5.

Vemurafenib therapy for stage IV melanoma with V600G-mutation.

Lang N, Weisser A, Enk A, Hassel JC.

J Dtsch Dermatol Ges. 2013 Dec;11(12):1198-9. doi: 10.1111/ddg.12200. Epub 2013 Sep 9. No abstract available.

PMID:
24016000
6.

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R.

J Transl Med. 2010 Jul 14;8:67. doi: 10.1186/1479-5876-8-67.

7.

Targeted therapies for cutaneous melanoma.

Kee D, McArthur G.

Hematol Oncol Clin North Am. 2014 Jun;28(3):491-505. doi: 10.1016/j.hoc.2014.02.003. Epub 2014 Apr 3. Review.

PMID:
24880943
8.

Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.

Jang S, Atkins MB.

Clin Pharmacol Ther. 2014 Jan;95(1):24-31. doi: 10.1038/clpt.2013.197. Epub 2013 Sep 30. Review.

PMID:
24080641
9.

[BRAF mutation detection in metastatic melanoma].

Dietel M, Enk A, Lehmann A, Bauer J, Garbe C, Kellner U, Kirchner T, Jung A, Kreipe H, Merkelbach-Bruse S, Büttner R, Rüschoff J, Schlake W, Schirmacher P, Penzel R, Stadler R.

Pathologe. 2012 Jul;33(4):352-6. doi: 10.1007/s00292-012-1609-5. German. No abstract available.

PMID:
22692278
10.

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.

Spagnolo F, Ghiorzo P, Queirolo P.

Oncotarget. 2014 Nov 15;5(21):10206-21. Review.

11.

Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.

Starz H, Gutschi M, Welzel J, Haas C.

J Dtsch Dermatol Ges. 2014 Feb;12(2):151-4. doi: 10.1111/ddg.12231. Epub 2013 Nov 18. No abstract available.

PMID:
24238398
12.

Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.

Owen JL, Lopez IE, Desai SR.

J Drugs Dermatol. 2015 May;14(5):509-10.

PMID:
25942671
13.

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.

Satzger I, Marks L, Kerick M, Klages S, Berking C, Herbst R, Völker B, Schacht V, Timmermann B, Gutzmer R.

Oncotarget. 2015 Nov 10;6(35):37895-905. doi: 10.18632/oncotarget.5634.

14.

Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?

Baroudjian B, Boussemart L, Routier E, Dreno B, Tao Y, Deutsch E, Blanchard P, Dhermain F, Vilcot L, Vagner S, Eggermont A, Mateus C, Robert C.

Eur J Dermatol. 2014 Mar-Apr;24(2):265-7. doi: 10.1684/ejd.2014.2300. No abstract available.

PMID:
24721778
15.

Community experience of vemurafenib for BRAF(V600) melanoma.

Hersey P.

Lancet Oncol. 2014 Apr;15(4):369-70. doi: 10.1016/S1470-2045(14)70079-8. Epub 2014 Feb 27. No abstract available.

PMID:
24582506
16.

Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.

Koers K, Francken AB, Haanen JB, Woerdeman LA, van der Hage JA.

J Clin Oncol. 2013 Jun 1;31(16):e251-3. doi: 10.1200/JCO.2012.45.3845. Epub 2013 Apr 8. No abstract available.

PMID:
23569313
17.

Strides in melanoma announced: maximizing value comes next.

Tuma RS.

J Natl Cancer Inst. 2011 Jul 6;103(13):997-9. doi: 10.1093/jnci/djr254. Epub 2011 Jun 21. No abstract available.

PMID:
21693727
18.

Targeted therapy in melanoma.

Kudchadkar RR, Smalley KS, Glass LF, Trimble JS, Sondak VK.

Clin Dermatol. 2013 Mar-Apr;31(2):200-8. doi: 10.1016/j.clindermatol.2012.08.013. Review.

PMID:
23438383
19.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.

Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.

PMID:
26433819
20.

Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets.

Flaherty KT.

Clin Exp Metastasis. 2012 Oct;29(7):841-6. doi: 10.1007/s10585-012-9488-y. Epub 2012 Jun 3.

PMID:
22661223

Supplemental Content

Support Center